Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × aflutinib × Thoracic × Clear all

Phase

Phase 2 29 Phase 3 5 Phase 1 5 Phase 1/2 4 Phase NA 3 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Pemetrexed 20 Carboplatin 19 Cisplatin 18 pembrolizumab 14 Docetaxel 12 Paclitaxel 9 Gemcitabine 7 Gefitinib 5 Drug Therapy 5 Bevacizumab 5 Erlotinib Hydrochloride 4 130-nm albumin-bound paclitaxel 4 anlotinib 3 Radiotherapy 3 Magnetic Resonance Spectroscopy 3 cemiplimab 2 aumolertinib 2 atezolizumab 2 apatinib 2 Standard of Care 2 Radiotherapy, Intensity-Modulated 2 Radiosurgery 2 Leucovorin 2 Dexamethasone 2 trametinib 1 toripalimab 1 tislelizumab 1 spartalizumab 1 sintilimab 1 rofecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

The First Affiliated Hospital of Henan University of Science and Technology

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡